<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57594">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02356276</url>
  </required_header>
  <id_info>
    <org_study_id>20150129</org_study_id>
    <nct_id>NCT02356276</nct_id>
  </id_info>
  <brief_title>Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer</brief_title>
  <acronym>HIPEC-01</acronym>
  <official_title>A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Tumor Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Tumor Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the efficacy of hyperthermic intraperitoneal
      chemotherapy in the treatment of patients with locally advanced gastric cancer after radical
      gastrectomy with D2 lymphadenectomy. It is a multicentric and randomised phase III trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver metastatic rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">584</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D2 lymphadenectomy and HIPEC and Systemic chemotherapy Intraoperative and postoperative hyperthermic intraperitoneal chemotherapy (twice HIPEC) were performed after radical gastrectomy with D2 lymphadenectomy, followed by 8 cycles of systemic chemotherapy. HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m^2, 43°C, 60min. Systemic chemotherapy (XELOX): Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>D2 lymphadenectomy+Systemic chemotherapy 8 cycles of systemic chemotherapy were performed after radical gastrectomy with D2 lymphadenectomy. Systemic chemotherapy (XELOX): Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>D2 lymphadenectomy</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <description>HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m^2, 43°C, 60min.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic chemotherapy (XELOX)</intervention_name>
    <description>Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine:
1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/ intolerance.</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <other_name>XELOX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 &lt; age ≤ 70 years old

          -  Male or Non pregnant female

          -  The Eastern Cooperative Oncology Group (ECOG) status 0-1

          -  T3 or T4 gastric adenocarcinoma (visual determination according to AJCC 2010 7th
             edition)

          -  No distance metastasis, eligible for D2 lymphadenectomy

          -  Have not received cytotoxic chemotherapy, radiotherapy or immunotherapy

          -  White blood cells &gt; 4,000/mm3

          -  neutrophils ≥ 1,500/mm3

          -  platelets ≥ 100,000/mm3

          -  hemoglobin&gt;9g/l

          -  Alanine transaminase (ALT) and aspartate aminotransferase (AST) &lt; or = 2.5 times
             upper limit of nominal (ULN)

          -  total bilirubin (TBIL) &lt; 1.5 times ULN

          -  serum creatinine &lt; 1 times ULN

          -  Having given written informed consent prior to any procedure related to the study

        Exclusion Criteria:

          -  Have other cancer within 5 years

          -  Existence of distance metastasis during surgey (M1)

          -  Prior malignant tumors with detectable signs of recurrence or distant metastasis

          -  Poorly controlled disease e.g. atrial fibrillation, stenocardia, cardiac
             insufficiency, persistent hypertension despite medicinal treatment, ejection
             fraction&lt;50%

          -  Epileptic seizures patients need medicine control

          -  Uncontroled mental disease or mental disorder

          -  Drug abuse or psychological or social factors affect the judgment of results

          -  Contraindication to any therapy contained in this regimen specific to the study

          -  Receiving other chemotherapy, radiotherapy or immunotherapy

          -  Without given written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shuzhong cui, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>Affiliated Tumor Hospital of Guangzhou Medical University Recruiting</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhiyuan fang, Ph.D</last_name>
    <phone>86020666736662012</phone>
    <email>fangjnu@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhiyuan fang, Ph.D</last_name>
      <phone>86020666736662012</phone>
      <email>fangjnu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>shuzhong cui, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 19, 2015</lastchanged_date>
  <firstreceived_date>January 29, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
